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Summary
Background: Brucellosis is a multisystem disease that may present with a broad spectrum of
clinical manifestations and complications. Neurobrucellosis is one of the complications.
Methods: In this study, we describe our experience in the diagnosis, treatment, and the final
outcomes of 20 patients with neurobrucellosis out of 305 patients with brucellosis, within a five-
year period between January 1999 and June 2004.
Results: The rate of neurobrucellosis was 6.6%. Twelve males and eight females with a mean age
of 37.4 years were investigated. Fever, headache, confusion, and gait disorders were the main
complaints. The duration of their complaints varied between one week and six months. On
physical examination, 13 patients had fever, six had neck stiffness and confusion, three hadmotor
deficit on either their upper or lower extremities, and four of them had diplopia. The Rose-Bengal
test and standard tube agglutination tests were positive in all of the patients. Brucella melitensis
was isolated from the blood of six of the 20 (30%) patients. Cerebrospinal fluid (CSF) was analyzed
in 18 patients. Pleocytosis with a mean value of 244  106 cells/L, and high protein levels were
detected in all. A low glucose level in the CSF was detected in ten patients. Patients were treated
medically and a complete resolution was achieved in all.
Conclusion: Patients with a Brucella infection occasionally manifest central nervous system
involvement. Clinicians, especially serving in endemic areas or serving patients coming from
endemic areas should consider the likelihood of neurobrucellosis in the patients with unex-
plained neurological and psychiatric symptoms, and should perform the necessary tests on blood
and CSF.
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Brucellosis, caused by microorganisms belonging to genus
Brucella, is endemic in many countries throughout the world
including Turkey.1 In 2004, the incidence of brucellosis in
Turkey was 25.67/100 000 population.2 It is a multisystem
disease that may present with a broad spectrum of clinical
manifestations and complications. Neurologic manifestations
of brucellosis occur in 3—5% of patients.3,4 The clinical
presentation of neurobrucellosis includes meningoencepha-
litis, meningovascular involvement, parenchymatous dys-
function, peripheral neuropathy/radiculopathy (PNP), and
various degrees of behavioral abnormalities.5 Among the
clinical manifestations, meningitis has been the most fre-
quent presentation in clinical series and usually presents in
an acute or chronic form.3,4,6,7
In this study we describe our experience in the diagnosis,
treatment, and final outcome of 20 patients with neurobru-
cellosis who were diagnosed and treated in our hospital.
Patients and methods
This prospective study was conducted at the Department of
Infectious Diseases and Clinical Microbiology of The Health
Ministry Ankara Training and Research Hospital between
January 1999 and June 2004. Our hospital is one of the largest
hospitals in the city, serving not only the 3 000 000 inhabi-
tants of Ankara, but the thousands of patients referred from
several primary and secondary healthcare centers located in
central Anatolia, and its periphery.
Patients aged 16 years, diagnosed with and treated for
brucellosis, were enrolled. All patients were evaluated for
central nervous system (CNS) involvement. Age, sex, clinical
symptoms and their duration at the time of admission, history
of ingestion of raw milk or milk products, pertinent physical
exam findings, and laboratory results were recorded for each
patient.
A diagnosis of brucellosis was established by one of the
following criteria: (1) isolation of Brucella spp in blood
samples or (2) a clinical and epidemiological presentation
consistent with brucellosis in the presence of a standard tube
agglutination test (STA) 1:160 or (3) a four-fold increase in
titers of STA.
All of the blood and cerebrospinal fluid (CSF) specimens
were cultured in BACTEC 9050 system and incubated for at
least 21 days. A seroagglutination test was carried out as
described.8 Complete blood count, erythrocyte sedimenta-
tion rate, C-reactive protein, liver, and renal function tests
were also obtained.
Patients with symptoms and clinical findings consistent
with neurobrucellosis and who had either of the following
criteria: (1) isolation of Brucella spp from CSF and/or demon-
stration of antibodies to Brucella spp in the CSF (at any titer)
in the presence of any abnormality of the CSF or (2) clinical
improvement with appropriate therapy, were considered to
have neurobrucellosis. CSF abnormalities were considered as
the presence of >10  106 cells/L, protein levels >45 mg/L,
or glucose levels 40 mg/dL or less than 40% of the con-
comitant blood glucose level.
Lumbar puncture was offered to all of the patients
who had symptoms and clinical findings consistent withneurobrucellosis. Computed tomography (CT) and/or mag-
netic resonance imaging (MRI) were performed on all patients
with neurobrucellosis. Electromyelography (EMG) was per-
formed when needed.
Ceftriaxone (2 g IV, q12h), plus doxycycline (100 mg PO,
q12h) and rifampin (600 mg/day PO) were given to patients
whohadmeningitis in thefirstmonthand thiswas followedbya
doxycycline and rifampin regimen until the end of therapy.
Doxycycline (100 mg PO, q12h) and rifampin (600 mg/day PO)
and trimethoprim/sulfamethoxazole (TMP/SMX) combination
therapy was given to patients who had polyradiculopathy.
Patientswere hospitalized for amonth and then seen regularly
eachmonth at the outpatient clinic. The duration of antibiotic
therapy in patients withmeningitis varied depending upon the
clinical response and CSF findings returning to normal. The
duration of treatment for brucellar meningitis was between
three and nine months, whereas in polyradiculopathy, it was
three months. After the completion of therapy, patients were
followed-up for up to 6 months at the outpatient clinic.
Statistical analysis
Data were analyzed using SPSS version 10.0. Chi-square tests,
Fisher’s exact tests and Mann—Whitney U tests were per-
formed, with p-values of <0.05 accepted as significant.
Results
During the five-year period, 305 patients with brucellosis
were treated at our clinic. Twenty of them (6.6%) had
neurobrucellosis and 12 of them were men. Mean age, gen-
der, whether they lived in a rural area, duration of com-
plaints, and history of previous treatment for brucellosis
were compared between the patients with and without
neurobrucellosis. Patients with neurobrucellosis were
younger (37.4  13.7 years) than the other group
(44.2  18.7 years) but the difference between these two
groups was not statistically significant ( p > 0.05). Similarly
no statistically significant difference was observed when the
other parameters were compared ( p > 0.05) (Table 1).
All the patients with neurobrucellosis had an epidemio-
logical risk factor for brucellosis. Thirteen of the 20 patients
(65%) lived in rural areas, 15 (75%) had consumed unpasteur-
ized dairy products, and 14 (70%) worked as either a farmer or
herdsman. Also, four patients had a history of brucellosis in
their family members. Six of them had a history of incom-
plete treatment for brucellosis before their admission to our
clinic. None of the patients had an underlying disease.
Fever and headache were the major presenting complaints
and were observed in 85% and 70%, respectively. The clinical
features of the neurobrucellosis cases are summarized in
Table 2. In 11 of the 20 (55%) patients, the duration of com-
plaints was less than one month. On physical examination, 13
patients had fever, six had neck stiffness and confusion, three
had motor deficit on either their upper or lower extremities,
and four of them had diplopia at lower gaze. Other physical
examination findings of the patients are shown in Table 2.
The main complaints and physical findings detected were
compared between the patients with and without neurobru-
cellosis. Headache was detected in 70% of patients with
neurobrucellosis compared to 31% in patients without
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Table 1 Main complaints and physical findings were compared between the patients with and without neurobrucellosis
Patients with
neurobrucellosis
(N = 20)
Patients without
neurobrucellosis
(N = 285)
Age 37.4  13.73 44.2  18.73 p > 0.05
Gender (M/F) 12/8 154/131 p > 0.05
Living in rural area 13 148 p > 0.05
Duration of complaints <1 month 11 90 p > 0.05
History of previous antibiotic usage 6 92 p > 0.05
Complaints
Headache 14 88 p < 0.001
Fever 17 209 p > 0.05
Sweating 13 196 p > 0.05
Nausea and vomiting 6 30 p = 0.02
Weakness 15 202 p > 0.05
Physical findings
Fever 13 198 p > 0.05
Laboratory findings
Mean WBC count (109/L) 6.920 6.983 p > 0.05
Mean CRP value (mg/dL) 4.72 4.77 p > 0.05
WBC, white blood cell; CRP, C-reactive protein.neurobrucellosis ( p < 0.001). Nausea and vomiting was
detected in 30% of patients with neurobrucellosis compared
to 11% in patients without neurobrucellosis ( p = 0.02). Other
findings are shown in Table 1.
Acute meningitis was an evident clinical finding in six
patients (patients 6, 9, 11, 14, 17, and 19). Cranial nerve
involvement was detected in patients 7, 10, 15, and 19, and
they had abducens nerve involvement. Motor deficit was
detected in the lower extremities of patients 12 and 13
whereas in patient 3 motor deficit was detected in both
the upper and lower extremities. Polyradiculopathy was
detected in patients 1 and 16. Neurological examination
was normal in patient 18.
Leukocytosis (white blood cells (WBC)10.5  109/L) was
found in two patients while one patient had leukopenia. The
erythrocyte sedimentation rate (ESR) was >40 mm/hour in
four of the patients. C-reactive protein levels were above
normal values in twelve patients.
A Rose-Bengal test and STA tests were positive in all of the
patients. Brucella melitensis was isolated from the blood of
six of them (30%) patients. We were able to perform CSF
analysis on 18 patients; two patients refused the procedure.
Laboratory results are shown in Table 3. Themedian STAvalue
of the patients was 1:640 and the median CSF Brucella
agglutination titer was 1:32. Pleocytosis ranged from 30 to
820  106 cells/L with a mean value of 244  106 cells/L,
with lymphocytic predominance. All had high protein levels,
from 48 to 484 mg/dL. A low glucose level in the CSF was
detected in ten patients. Brucella melitensis was isolated
from the CSF of patients 7, 10, and 15. A bloody tap was
present in two of them. Lumbar puncture was also performed
in 18 of the patients (21%) without neurobrucellosis who had
headaches, and all of them had normal CSF values.
Computerized brain tomography or MRI findings were
normal in 14 patients. Nonspecific changes were detected
in patients 6 and 10. A hyperintense lesion due to subduralhematoma in the left frontoparietal region was detected in
patient 19, and this lesion improved with treatment. Other
CT/MRI changes are shown in Table 3. Electromyelography
was performed on patients 1 and 16 and there were findings
compatible with polyradiculopathy in these patients. No
other causes of polyradiculopathy were detected in these
patients and brucellosis was thought to be the cause.
Male and female patients with neurobrucellosis were
compared separately with respect to the parameters of mean
age, living in a rural area, duration of complaints, serum
white blood cell count, pleocytosis in CSF, and CSF protein
and glucose level changes. Males (31.5  11.8 years) were
younger than females (46.1  11.8 years) and this difference
was statistically significant ( p = 0.015). Male patients lived
mostly in rural areas whereas female patients lived mostly in
urban areas; this difference was statistically significant
( p = 0.019). No statistically significant difference was
observed when the other parameters were compared
( p > 0.05).
Doxycycline plus rifampin plus ceftriaxone combination
therapy was given to 19 patients who had meningitis due to
brucellosis. A combination of doxycycline plus rifampin plus
streptomycin was initially given to one of the patients
(patient 15) but the treatment was changed to a combina-
tion of doxycycline plus rifampin plus ceftriaxone when
meningitis was diagnosed. Clinical response and the return
of CSF findings to normal values were our main criteria for
the duration of treatment, and the duration of treatment
was three months in 12 patients, six months in six patients,
and nine months in one patient who had meningitis due to
brucellosis. Doxycycline plus rifampin and TMP/SMX com-
bination with a duration of three months was given to the
patient who had polyradiculopathy due to brucellosis.
There was a good clinical response, and improvement on
electromyelography findings was detected at the end of the
treatment.
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Table 2 Clinical features, physical examination findings, and treatment protocols of 20 patients with neurobrucellosis
No. Age/Gender Complaints Physical findings Therapy Duration of
therapy
Outcome
1 26/M Headache, vomiting,
dizziness, fever
Romberg sign (+), ataxia
polyradiculopathy
DOX + RIF + CRO 3 months Recovered
2 43/M Low grade fever,
headache, neck pain
Restricted neck
movement
DOX + RIF + CRO 3 months Recovered
3 38/F Fever, headache,
inability to walk
Motor deficit 3/5 in
upper extremities
and 1/5 in lower
extremities
DOX + RIF + CRO 3 months Gait disorder
4 36/M Fever, headache,
speech disorder
Dysarthria DOX + RIF + CRO 3 months Recovered
5 55/F Fever, headache, pain
on the left side of the
face, left hip and arm pain
Left hemihypoesthesia DOX + RIF + CRO 3 months Recovered
6 56/F Fever, headache,
confusion
Neck stiffness, confusion DOX + RIF + CRO 3 months Recovered
7 19/M Diplopia and restriction
of lateral gaze on left
eye and headache
Diplopia and paralysis of
left abducens nerve
DOX + RIF + CRO 3 months Recovered
8 57/F Fever, headache,
lumbar pain
Sensitivity on
lumbosacral
and sacroiliac joints
DOX + RIF + CRO 6 months Recovered
9 30/F Fever, headache,
confusion
Lack of orientation
and cooperation
DOX + RIF + CRO 6 months Recovered
10 23/M Restriction of lateral
gaze on right eye
Paralysis of right
abducens and
papilledema
DOX + RIF + CRO 3 months Recovered
11 27/M Fever, headache,
nausea, vomiting,
sleep tendency
Neck stiffness,
disorientation
and confusion
DOX + RIF + CRO 3 months Recovered
12 56/F Fever, muscle weakness
in lower extremities
Muscle weakness 3/5 in
lower extremities
DOX + RIF + CRO 9 months Recovered
13 48/M Fever, urinary
incontinence,
muscle weakness in
lower extremities
Motor deficit 2/5
in right lower
extremities
and 3/5 in left
lower extremities
DOX + RIF + CRO 6 months Gait disorder
14 39/M Fever, headache Neck stiffness DOX + RIF + CRO 6 months Recovered
15 29/F Fever, headache, diplopia Medial deviation
in left eye
and indistinctness
of optic disc borders
DOX + RIF + CRO 6 months Recovered
16 71/M Fever and numbness
on the distal part
of the right leg
Polyradiculopathy
and neuropathy at
the lower extremities
DOX + RIF + TMP/SMX 3 months Recovered
17 31/M Fever, weakness,
headache
Neck stiffness,
confusion
DOX + RIF + CRO 3 months Recovered
18 17/M Fever, headache,
vomiting and nausea,
weight loss
Splenomegaly DOX + RIF + CRO 3 months Recovered
19 49/F Headache and
confusion, fever
Neck stiffness, confusion
and paralysis of left
abducens and papilledema
DOX + RIF + CRO 6 months Recovered
20 51/M Fever and urinary
incontinence
Hepatomegaly DOX + RIF + CRO 3 months Recovered
DOX, doxycycline; RIF, rifampin; CRO, ceftriaxone; TMP/SMX, trimethoprim/sulfamethoxazole.
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Table 3 Some of the laboratory findings and imaging findings of 20 patients with neurobrucellosis
No. STA Blood/CSF
culture
CSF cell
count  106/L
CSF protein
level (mg/dL)
CSF/blood
glucose level
(mg/dL)
CSF Brucella
agglutination
titer
Imaging findings
1 1:1280 380 484 31/98 1:128 CT brain: normal; EMG:
polyradiculopathy
2 1:640 + 30 135 44/127 1:16 CT brain: normal;
MRI spine: C3—4
spondylodiscitis, EMG:
generalized
sensorimotor PNP
3 1:640 200 188 60/80 1:64 CT brain: normal
4 1:1280 70 246 38/121 1:128 CT brain: normal
5 1:640 ND CT brain: hypoattenuation
due to lacunar infarct at
bilateral capsula
externa and left
centrum semiovale
6 1:320 820 125 40/95 1:8 MRI brain: ischemic
changes at
supratentorial
white matter
7 1:2560 + (B, CSF) 170 51 46/103 1:32 CT brain: normal
8 1:2560 30 68 100/225 1:32 CT brain: normal
9 1:1280 + 30 72 35/95 1:16 CT brain: normal
10 1:160 + (CSF) 200 324 29/117 1:16 MRI brain: millimetric
hyperintense lesions on
left forceps minor
11 1:320 190 134 29/144 1:4 CT brain: normal
12 1:160 810 312 51/105 1:32 MRI brain: ischemic
gliotic signal
changes on left
frontoparietal region
13 1:320 30 138 45/98 1:64 CT brain: normal
14 1:320 500 48 50/135 1:32 CT brain: normal
15 1:640 + (CSF) 80 101 44/126 1:16 CT brain: normal
16 1:1280 ND CT brain: normal,
EMG: polyradiculopathy:
17 1:2560 + 150 76 50/98 1:4 CT brain: normal
18 1:2560 + 30 53 45/93 1:32 CT brain: normal
19 1:640 + 600 115 35/150 1:32 MRI brain: hyperintense
lesion due to subdural
hematoma in the left
frontoparietal region
20 1:1280 70 118 23/118 1:128 MRI brain: leptomeningeal
contrast involvement
around prepontine region,
cavernous sinuses
STA, standard tube agglutination test; CSF, cerebrospinal fluid; CT, computed tomography; EMG, electromyelography; MRI, magnetic
resonance imaging; PNP, peripheral neuropathy.In the treatment of patients with normal CSF values, two
drug combinations were used, streptomycin plus doxycycline
or rifampin plus doxycycline. The duration of the therapy was
six weeks for all.
Lumbar puncture was repeated at the end of the fourth
week on the same 18 neurobrucellosis patients who had
undergone this procedure before treatment. Although there
was a decrease in cell count and protein in the CSF, all the
values were above the normal range. All patients recoveredwith medical therapy, but sequelae resulted for patients 3
and 13—gait disorders due to motor deficit.
Discussion
The reported incidence of neurological complications of
brucellosis have ranged from 0% to 17.8%,9,10 the majority
being around 2—5%.3,4,11 The incidence in this study was
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studies. Our hospital is one of the tertiary-care hospitals
for our region; most patients with complications such as
neurobrucellosis are referred to us, and uncomplicated cases
are treated in their hometowns. This might be the cause of
our relatively high incidence.
The demographics as well as clinical characteristics of the
patients in this study were similar to those of groups of
patients with neurobrucellosis described elsewhere.3,4,6,7,9
In our study males were younger than females. As most of our
male patients were shepherds of working age, this might be
the cause of the age difference in our study.
Clinical manifestations of neurobrucellosis vary widely,
and meningitis is the most frequent manifestation. However,
it has been noted that <50% of the patients with brucellar
meningitis exhibit meningeal signs.3 The diagnosis of brucel-
lar meningitis depends on the demonstration of meningeal
inflammation, abnormal CSF findings, and direct or indirect
evidence of Brucella in the CSF.3,4,12,13 Neck stiffness or some
other indication of meningeal irritation was present in 27.3%
of the cases that we reviewed; on the other hand pleocytosis
and an increased protein level in the CSF were detected in all
the neurobrucellosis patients from whom CSF was obtained.
These findings indicate that the examination of the CSFmight
be more helpful than the physical examination for the diag-
nosis of neurobrucellosis in all patients with brucellosis pre-
senting any neurological symptoms including unexplained
headache. Parenchymatous involvement of the CNS in bru-
cellosis may occur at any location including cerebellum,
spinal cord, and cerebellar white matter. Meningitis usually
accompanies the parenchymatous lesions.3,14 One of our
patients had symptoms attributed to parenchymatous invol-
vement together with meningitis.
Subarachnoid hemorrhage, intracerebral hemorrhage,
subthalamic hemorrhage, and cerebral venous thrombosis
have been reported as meningovascular complications of
neurobrucellosis by various authors.3,15—17 Like these cases,
subdural hematoma was detected in one of our patients
during the course of treatment for brucellar meningitis
and there was no history of head trauma, no evidence of
coagulopathy, or endocarditis at the time of hemorrhage.
Meningovascular involvement was most likely in this patient
and the patient recovered with medical therapy for brucel-
losis.18
Radiculopathy or neuropathy associated with muscle
weakness could be seen as a clinical syndrome in patients
with neurobrucellosis.3,19 Polyneuropathy associated with
neurobrucellosis confirmed by electromyelographic findings
was detected in some of our patients and improved with
medical treatment of the neurobrucellosis. The cranial
nerves mostly involved were the abducens, facial, and ves-
tibulocochlear nerves.3 Sixth nerve involvement was
observed in four patients in our study.
The treatment of neurobrucellosis poses special problems
and there is no single opinion regarding the optimal regimen.
Nevertheless, most authorities recommend the use of dox-
ycycline in combination with two or more antimicrobial
agents that penetrate the blood—brain barrier well.5,11
Rifampin, TMP/SMX, doxycycline, and ceftriaxone achieve
high levels in the CSF.11 A combination of doxycycline plus
rifampin and/or TMP/SMX with a duration of six weeks to one
year was most often used in other studies for the treatmentof neurobrucellosis.3,4,15,18 On the other hand in their study,
Bodur et al. treated their patients successfully with a com-
bination of doxycycline plus rifampin and ceftriaxone.10
Although some authors recommend a 2—4 month course of
therapy, the duration of therapy must be individualized and
some patients may require longer courses.3,20 Some authors
recommend treatment until the patient recovers and the CSF
findings return to normal.3,4,11
As with the patients with brucellar meningitis, there was a
treatment difficulty in patients with radiculopathy or per-
ipheral neuropathy due to brucellosis. A combination therapy
that consisted of doxycycline plus rifampin and TMP/SMX has
been selected in some reported studies.3,18 The duration of
treatment in these studies was between three and six
months. Similarly, a doxycycline plus rifampin and TMP/
SMX combination was preferred for our patients in this
situation.
Patients with neurobrucellosis generally respond well to
treatment and recover completely from neurologic deficits,
but in some patients, residual, permanent deficits may
remain.3,7 Complete cure was obtained in our patients but
sequelae resulted in two patients. The generally good prog-
nosis in the cases reviewed supports currently published
knowledge.
In conclusion, CNS involvement is a serious complication
of brucellosis and clinical presentation is heterogeneous.
Clinicians, especially those serving in endemic areas, should
consider the likelihood of neurobrucellosis in patients with
unexplained neurological and psychiatric symptoms and
should perform the necessary tests on blood and CSF. A
combination of doxycycline plus rifampin and ceftriaxone
regimen could be a treatment option for these patients.
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